A longitudinal study of intact platelet 3H-imipramine binding in 12 normal human subjects.
Most investigators have measured binding of 3H-imipramine to platelet membranes, but some of the preparations may have contained varying proportions of intracellular protein because of contamination with incompletely lysed platelets. Since binding to membranes has been expressed with reference to the amount of protein in the membrane preparation, it is not surprising that there are discrepancies and a wide range of reported values for platelet imipramine binding in the literature. We have now completed a 9-month study of the binding of 3H-imipramine to intact platelets obtained monthly from 12 normal subjects. Using the intact platelet assay, as described by Friedl and Propping, we found that both Bmax and Kd for 3H-imipramine binding exhibited large month-to-month variations and no consistent seasonal trend was observed. The substantial variation in both Bmax and Kd among normal subjects and among samples obtained from the same individual at different times may limit the clinical usefulness of these measurements. A single blood sample is unlikely to give reliable values for Bmax and Kd for comparison purposes.
Goziotis
A
A
Psychopharmacology Unit, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.
Tang
S W
SW
D000328:Adult; D001792:Blood Platelets / Q000378:metabolism*; D002352:Carrier Proteins; D005260:Female; D006801:Humans; D007099:Imipramine / Q000493:pharmacokinetics*; D008137:Longitudinal Studies; D008297:Male; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter / Q000378:metabolism*; D012016:Reference Values
D002352:Carrier Proteins; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter; C027775:imipramine receptor; D007099:Imipramine